FebriDx and Rapid UTI PCR Show the Next Step Is Site-by-Site Rollout

Clearance is no longer the finish line; diagnostics are now won through reimbursement, distribution, and repeatable site activation.

Updated

What is this trend?

Diagnostics winners are now defined less by regulatory clearance than by how quickly they can activate, reimburse, and scale each individual testing site.

  • CLIA waiver opens the market; site activation determines the pace of revenue.
  • FebriDx is moving from pilot to scale across urgent care and other CLIA-waived settings.
  • Rapid PCR is expanding beyond respiratory use into near-patient stewardship workflows like UTI.
  • Distribution, reimbursement, and repeatable rollout playbooks are becoming the real moat.
  • Closed-loop workflows matter: testing must connect cleanly to ordering, results, and follow-up.

What’s the latest?

How it developed

  1. Decentralized diagnostics become workflow platforms, blood screening enters clinical care, and liquid biopsy turns decision support
    • Regulated Decentralized Diagnostics Are Becoming Workflow Platforms
  2. Companion diagnostics become commercial platforms, FDA makes AI validation the moat, and pathology consolidates
    • Decentralized Testing Expansion
  3. ctDNA Gates Therapy, AI Moves Into Workflow, and Distribution Becomes the New Moat
    • Decentralized Testing Expansion
  4. Diagnostics move into care pathways, CMS resets pricing, and routing becomes the new moat
    • Quest and Waters Turn At-Home HPV Into a Routed Care Program

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in Diagnostics & Informatics

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.